Leann Kuhlmann-Qi (MBA) is an accomplished business professional with considerable expertise in managing early-stage biotechnology companies. She began her career by starting Kuhlmann Consulting, where she was responsible for grant administration for several clients and spearheaded a financial product to accompany a New York Times best-seller product. Leann's current roles as CEO of Cell Origins includes leading its strategic development, which have provided her with extensive and invaluable experience in corporate operations, setting her apart as an true innovator in the field.

Jessica Newton-Northup (MS) is a phage display expert with over two decades of laboratory experience in the field. She has published countless research articles on phage display and peptide discovery and contributed to various research grants. Throughout her career, Jessica has demonstrated an extraordinary aptitude for problem-solving in peptide drug discovery and development as a leader of successful teams in both academic and early-stage biotechnological laboratories. At Cell Origins, she puts her extensive knowledge and experience to use by developing innovative phage display libraries and by leading our laboratory services.

Mette Soendergaard (PhD) is a pioneering scientist with numerous accomplishments in the field of phage display technology. She brings nearly two decades of experience in developing novel methods of affinity selections and phage and peptide assay analyses to Cell Origins. Her work has specifically focused on implementing multi-tier phage display selections to identify cancer-targeting peptides with improved pharmacokinetics. In her role at Cell Origins, Mette is intent on pushing phage display innovation forward by optimizing and streamlining drug discovery. In her opinion, this needs to be done by creating phage display libraries of unsurpassed quality with built-in screening options and combining these with custom multi-tier affinity selections.